Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
November 09, 2023 07:00 ET
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
Arvinas Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 07, 2023 07:00 ET
|
Arvinas Inc.
– Enrollment continues in the 2L Phase 3 VERITAC-2 trial and study lead-in for the VERITAC-3 1L Phase 3 trial with vepdegestrant; Top-line data readout for VERITAC-2 remains on-track for 2H 2024 – –...
Arvinas to Participate in Upcoming Investor Conferences
November 02, 2023 07:00 ET
|
Arvinas Inc.
NEW HAVEN, Conn., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Potential of Arvinas’ PROTAC® AR Degraders Reinforced by 11.1 months rPFS with Bavdegalutamide and Updated Positive Interim Data from Second Generation ARV-766 in mCRPC
October 22, 2023 07:00 ET
|
Arvinas Inc.
– Data presented at the European Society for Medical Oncology from the Phase 1/2 trial with bavdegalutamide showed 11.1 months radiographic progression free survival in mCRPC patients with tumors...
Arvinas Gives Back to Local Greater New Haven Community in Second Annual Impact Day
October 18, 2023 07:00 ET
|
Arvinas Inc.
NEW HAVEN, Conn., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas Announces Upcoming Bavdegalutamide Poster Presentation at ESMO Congress 2023
October 15, 2023 18:07 ET
|
Arvinas Inc.
NEW HAVEN, Conn., Oct. 15, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentation at ESMO Congress 2023
October 15, 2023 18:05 ET
|
Arvinas Inc.
NEW HAVEN, Conn. and NEW YORK, Oct. 15, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced they will present updated Phase 1/2 data for vepdegestrant...
Emerging Landscape of Targeted Protein Degradation Therapeutics, 2023 Research Report - Rapid Technology Advances Bolster a Robust Therapeutic Pipeline
September 21, 2023 04:18 ET
|
Research and Markets
Dublin, Sept. 21, 2023 (GLOBE NEWSWIRE) -- The "Emerging Landscape of Targeted Protein Degradation Therapeutics" report has been added to ResearchAndMarkets.com's offering. This research report...
Arvinas to Participate in Upcoming Investor Conferences
September 01, 2023 07:00 ET
|
Arvinas Inc.
NEW HAVEN, Conn., Sept. 01, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 08, 2023 07:00 ET
|
Arvinas Inc.
– Enrollment continues globally in multiple clinical studies of vepdegestrant (ARV-471), including VERITAC-2 2L Phase 3 trial and study lead-in for the VERITAC-3 1L Phase 3 trial, both in ER+/HER2-...